The combination of TPL2 knockdown and TNFα causes synthetic lethality via caspase-8 activation in human carcinoma cell lines

Oksana B. Serebrennikova, Maria D. Paraskevopoulou, Elia Aguado-Fraile, Vasiliki Taraslia, Wenying Ren, Geeta Thapa, Jatin Roper, Keyong Du, Carlo M. Croce, and Philip N. Tsichlis
PNAS July 9, 2019 116 (28) 14039-14048; first published June 25, 2019 https://doi.org/10.1073/pnas.1901465116

  1. Contributed by Carlo M. Croce, May 21, 2019 (sent for review January 29, 2019; reviewed by Emad S. Alnemri and Wafik El-Deiry)

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Significance

Tumor necrosis factor α (TNFα) fails to induce apoptosis in most tumor cells. Defining the mechanism(s) responsible for the protection of these cells from TNFα-induced apoptosis may have significant therapeutic implications. Here, we show that tumor progression locus-2 (TPL2), a MAP3 kinase activated by TNFα, protects from TNFα-induced apoptosis by preventing the activation of caspase-8, and that the combination of TPL2 knockdown and TNFα treatment induces synthetic lethality. More important, sensitivity to synthetic lethality can be predicted from the gene expression profiles of the tumor cells. In addition to their therapeutic potential, these results identify an important node in TNFα signaling.

Abstract

Most normal and tumor cells are protected from tumor necrosis factor α (TNFα)-induced apoptosis. Here, we identify the MAP3 kinase tumor progression locus-2 (TPL2) as a player contributing to the protection of a subset of tumor cell lines. The combination of TPL2 knockdown and TNFα gives rise to a synthetic lethality phenotype via receptor-interacting serine/threonine-protein kinase 1 (RIPK1)-dependent and -independent mechanisms. Whereas wild-type TPL2 rescues the phenotype, its kinase-dead mutant does not. Comparison of the molecular events initiated by small interfering RNA for TPL2 (siTPL2) ± TNFα in treatment-sensitive and -resistant lines revealed that the activation of caspase-8, downstream of miR-21-5p and cFLIP, is the dominant TPL2-dependent event. More important, comparison of the gene expression profiles of all of the tested cell lines results in the clustering of sensitive and resistant lines into distinct groups, providing proof of principle for the feasibility of generating a predictive tool for treatment sensitivity.

Footnotes

  • ↵1Present address: Clinical Biomarkers Department, Agios Pharmaceuticals, Cambridge, MA 02139.

  • ↵2Present address: Department of Medicine, Tufts Medical Center, Boston, MA 02111.

  • ↵3Present address: Division of Gastroenterology, Department of Medicine, Duke University, Durham, NC 27710.

  • ↵4To whom correspondence may be addressed. Email: carlo.croce{at}osumc.edu or philip.tsichlis{at}osumc.edu.

  • Author contributions: O.B.S. and P.N.T. designed research; O.B.S., M.D.P., E.A.-F., V.T., W.R., and G.T. performed research; J.R., K.D., and C.M.C. contributed new reagents/analytic tools; O.B.S., M.D.P., and E.A.-F. analyzed data; O.B.S. and P.N.T. wrote the paper; and M.D.P. contributed the bioinformatics analyses.

  • Reviewers: E.S.A., Thomas Jefferson University; and W.E.-D., Brown University.

  • The authors declare no conflict of interest.

  • This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1901465116/-/DCSupplemental.

Published under the PNAS license.

References

  1. ↵
    1. D. Tracey,
    2. L. Klareskog,
    3. E. H. Sasso,
    4. J. G. Salfeld,
    5. P. P. Tak
    , Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther. 117, 244–279 (2008).
    OpenUrlCrossRefPubMed
  2. ↵
    1. J. V. Falvo,
    2. A. V. Tsytsykova,
    3. A. E. Goldfeld
    , Transcriptional control of the TNF gene. Curr. Dir. Autoimmun. 11, 27–60 (2010).
    OpenUrlCrossRefPubMed
  3. ↵
    1. C. Y. Wang,
    2. M. W. Mayo,
    3. R. G. Korneluk,
    4. D. V. Goeddel,
    5. A. S. Baldwin Jr
    , NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680–1683 (1998).
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. S. Kreuz,
    2. D. Siegmund,
    3. P. Scheurich,
    4. H. Wajant
    , NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 21, 3964–3973 (2001).
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. O. Micheau,
    2. S. Lens,
    3. O. Gaide,
    4. K. Alevizopoulos,
    5. J. Tschopp
    , NF-kappaB signals induce the expression of c-FLIP. Mol. Cell. Biol. 21, 5299–5305 (2001).
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. M. J. Bertrand et al
    ., cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30, 689–700 (2008).
    OpenUrlCrossRefPubMed
  7. ↵
    1. L. Wang,
    2. F. Du,
    3. X. Wang
    , TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133, 693–703 (2008).
    OpenUrlCrossRefPubMed
  8. ↵
    1. Y. Dondelinger et al
    ., RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ. 20, 1381–1392 (2013).
    OpenUrlCrossRefPubMed
  9. ↵
    1. I. Jaco et al
    ., MK2 phosphorylates RIPK1 to prevent TNF-induced cell death. Mol. Cell 66, 698–710.e5 (2017).
    OpenUrlCrossRefPubMed
  10. ↵
    1. Y. Dondelinger et al
    ., NF-κB-independent role of IKKα/IKKβ in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during TNF signaling. Mol. Cell 60, 63–76 (2015).
    OpenUrlCrossRefPubMed
  11. ↵
    1. M. B. Menon et al
    ., p38MAPK/MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection. Nat. Cell Biol. 19, 1248–1259 (2017).
    OpenUrlCrossRefPubMed
  12. ↵
    1. V. Kondylis et al
    ., NEMO prevents steatohepatitis and hepatocellular carcinoma by inhibiting RIPK1 kinase activity-mediated hepatocyte apoptosis. Cancer Cell 28, 582–598 (2015).
    OpenUrlCrossRef
  13. ↵
    1. K. M. Erny,
    2. J. Peli,
    3. J. F. Lambert,
    4. V. Muller,
    5. H. Diggelmann
    , Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis. Oncogene 13, 2015–2020 (1996).
    OpenUrlPubMed
  14. ↵
    1. C. Patriotis,
    2. A. Makris,
    3. S. E. Bear,
    4. P. N. Tsichlis
    , Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc. Natl. Acad. Sci. U.S.A. 90, 2251–2255 (1993).
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. J. D. Ceci et al
    ., Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev. 11, 688–700 (1997).
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. C. D. Dumitru et al
    ., TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103, 1071–1083 (2000).
    OpenUrlCrossRefPubMed
  17. ↵
    1. L. A. Mielke et al
    ., Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production. J. Immunol. 183, 7984–7993 (2009).
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. K. Gkirtzimanaki et al
    ., TPL2 kinase is a suppressor of lung carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 110, E1470–E1479 (2013).
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. O. B. Serebrennikova et al
    ., Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apcmin mice by inhibiting IL-10 secretion and regulatory T-cell generation. Proc. Natl. Acad. Sci. U.S.A. 109, E1082–E1091 (2012).
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. H. W. Lee,
    2. H. Y. Choi,
    3. K. M. Joo,
    4. D. H. Nam
    , Tumor progression locus 2 (Tpl2) kinase as a novel therapeutic target for cancer: Double-sided effects of Tpl2 on cancer. Int. J. Mol. Sci. 16, 4471–4491 (2015).
    OpenUrlCrossRef
  21. ↵
    1. Y. J. Jeon et al
    ., A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 112, E3355–E3364 (2015).
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. M. Irmler et al
    ., Inhibition of death receptor signals by cellular FLIP. Nature 388, 190–195 (1997).
    OpenUrlCrossRefPubMed
  23. ↵
    1. K. Nakano,
    2. K. H. Vousden
    , PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683–694 (2001).
    OpenUrlCrossRefPubMed
  24. ↵
    1. J. Yu,
    2. L. Zhang,
    3. P. M. Hwang,
    4. K. W. Kinzler,
    5. B. Vogelstein
    , PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7, 673–682 (2001).
    OpenUrlCrossRefPubMed
  25. ↵
    1. H. Sakurai,
    2. H. Miyoshi,
    3. J. Mizukami,
    4. T. Sugita
    , Phosphorylation-dependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1. FEBS Lett. 474, 141–145 (2000).
    OpenUrlCrossRefPubMed
  26. ↵
    1. Y. Hirata,
    2. M. Takahashi,
    3. T. Morishita,
    4. T. Noguchi,
    5. A. Matsuzawa
    , Post-translational modifications of the TAK1-TAB complex. Int. J. Mol. Sci. 18, E205 (2017).
    OpenUrl
  27. ↵
    1. M. A. Hughes et al
    ., Co-operative and hierarchical binding of c-FLIP and caspase-8: A unified model defines how c-FLIP isoforms differentially control cell fate. Mol. Cell 61, 834–849 (2016).
    OpenUrlCrossRefPubMed
  28. ↵
    1. C. Kantari,
    2. H. Walczak
    , Caspase-8 and bid: Caught in the act between death receptors and mitochondria. Biochim. Biophys. Acta 1813, 558–563 (2011).
    OpenUrlCrossRefPubMed
  29. ↵
    1. Y. Lin,
    2. A. Devin,
    3. Y. Rodriguez,
    4. Z. G. Liu
    , Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 13, 2514–2526 (1999).
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. J. W. Kim,
    2. E. J. Choi,
    3. C. O. Joe
    , Activation of death-inducing signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP. Oncogene 19, 4491–4499 (2000).
    OpenUrlCrossRefPubMed
  31. ↵
    1. Z. L. Chu et al
    ., Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc. Natl. Acad. Sci. U.S.A. 94, 10057–10062 (1997).
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. C. Polytarchou et al
    ., Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res. 71, 4720–4731 (2011).
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. S. Das et al
    ., Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J. Biol. Chem. 280, 23748–23757 (2005).
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. P. Wang et al
    ., PUMA is directly activated by NF-kappaB and contributes to TNF-alpha-induced apoptosis. Cell Death Differ. 16, 1192–1202 (2009).
    OpenUrlCrossRefPubMed
  35. ↵
    1. Z. T. Schug,
    2. F. Gonzalvez,
    3. R. H. Houtkooper,
    4. F. M. Vaz,
    5. E. Gottlieb
    , BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. Cell Death Differ. 18, 538–548 (2011).
    OpenUrlCrossRefPubMed
  36. ↵
    1. C. Maas,
    2. E. de Vries,
    3. S. W. Tait,
    4. J. Borst
    , Bid can mediate a pro-apoptotic response to etoposide and ionizing radiation without cleavage in its unstructured loop and in the absence of p53. Oncogene 30, 3636–3647 (2011).
    OpenUrlCrossRefPubMed
  37. ↵
    1. Y. Deng,
    2. Y. Lin,
    3. X. Wu
    , TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16, 33–45 (2002).
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. X. M. Sun,
    2. S. B. Bratton,
    3. M. Butterworth,
    4. M. MacFarlane,
    5. G. M. Cohen
    , Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J. Biol. Chem. 277, 11345–11351 (2002).
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. O. E. Pardo et al
    ., Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol. Cell. Biol. 23, 7600–7610 (2003).
    OpenUrlAbstract/FREE Full Text
View Full Text

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top
Article Alerts
Email Article
Citation Tools
Request Permissions
The combination of TPL2 knockdown and TNFα causes synthetic lethality via caspase-8 activation in human carcinoma cell lines
Oksana B. Serebrennikova, Maria D. Paraskevopoulou, Elia Aguado-Fraile, Vasiliki Taraslia, Wenying Ren, Geeta Thapa, Jatin Roper, Keyong Du, Carlo M. Croce, Philip N. Tsichlis
Proceedings of the National Academy of Sciences Jul 2019, 116 (28) 14039-14048; DOI: 10.1073/pnas.1901465116
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Proceedings of the National Academy of Sciences: 116 (29)
Current Issue

Submit

Article Classifications

Jump to section

You May Also be Interested in

Chemical evidence suggests ritual use of psychoactive plants used to brew ayahuasca in pre-Columbian Bolivia. Image courtesy of Juan V. Albarracin-Jordan and José M. Capriles.
Hints of ayahuasca in pre-Columbian rituals
Chemical evidence suggests ritual use of psychoactive plants used to brew ayahuasca in pre-Columbian Bolivia.
Image courtesy of Juan Albarracin-Jordan and José M. Capriles.
Changes in subarachnoid and intracerebral spaces, including superior sagittal sinus (1) and ventricles (2), of cosmonauts. Image courtesy of R. Maxine Rühl.
Brain fluid shifts following spaceflight
Volume of cosmonauts’ brain ventricles increased by an average of 12% after spaceflight—a potential mechanism to cope with increased brain fluid volume, a study suggests.
Image courtesy of R. Maxine Rühl.
PNAS Profile of NAS member and cell biologist Junying Yuan
Featured Profile
PNAS Profile of NAS member and cell biologist Junying Yuan
Image courtesy of Aaron Washington for Harvard Medical School.

Similar Articles